Does oral administration of dabigatran etexilate, a direct thrombin inhibitor, achieve clinical significant concentrations of dabigatran and thrombin inhibiting activity in vitreous and subretinal fluid?
Completed
- Conditions
- Rhegmatogenous retinal detachment.
- Registration Number
- NL-OMON23085
- Lead Sponsor
- Het Oogziekenhuis RotterdamRotterdams Oogheelkundig Instituut
- Brief Summary
Mulder VC, Kluft C, van Etten PG, La Heij EC, van Meurs JC. Higher vitreous concentrations of dabigatran after repeated oral administration. Acta Ophthalmol. 2017; 95(4): e345-e346.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 24
Inclusion Criteria
Age > 18 years
- Informed consent
Exclusion Criteria
- Using other anticoagulants (e.g. acenocoumarol, heparin etc)
- Using medication that increases risk of GI bleeding (e.g. aspirin, NSAIDs, SSRIs, oral corticosteroids).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method evels of dabigatran in vitreous, subretinal fluid and plasma. <br /><br>Antithrombin activity in vitreous and subretinal fluid and plasma.<br>
- Secondary Outcome Measures
Name Time Method